{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:07:01Z","timestamp":1782857221339,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011892","name":"Kaohsiung Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tjog.2025.12.015","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:47:32Z","timestamp":1782485252000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating homologous recombination status and the efficacy\/safety of PARP inhibitors in advanced epithelial ovarianl cancer: A single-institute preliminary experience"],"prefix":"10.1016","volume":"65","author":[{"given":"Chen-Hsuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Che","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chou","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.tjog.2025.12.015_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: a global assessment by world region and human development index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int J Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.tjog.2025.12.015_bib2","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"issue":"7035","key":"10.1016\/j.tjog.2025.12.015_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"9737","key":"10.1016\/j.tjog.2025.12.015_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.tjog.2025.12.015_bib5","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.tjog.2025.12.015_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2025.12.015_bib7","unstructured":"ACT HRDTM testing, ACT Genomics Co., LTD. https:\/\/cdn.prod.website-files.com\/656d822c2779eb3044b7d03c\/65bc55a1c6437dcda59c521c_ACT-HRD_Brochure_TC.pdf."},{"key":"10.1016\/j.tjog.2025.12.015_bib8","unstructured":"Sofiva HRD testing, Sofiva Genomics. https:\/\/www.sofivagenomics.com.tw\/Product\/ProductIndex?productNo=PD2024080038."},{"issue":"8","key":"10.1016\/j.tjog.2025.12.015_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/ijgc-2022-004211","article-title":"Homologous recombination deficiency in newly diagnosed FIGO stage III\/IV high-grade epithelial ovarian cancer: a multi-national observational study","volume":"33","author":"Morgan","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.tjog.2025.12.015_bib10","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.tjog.2025.12.015_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.tjog.2025.12.015_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"SOLO1 investigators. Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.tjog.2025.12.015_bib13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.12.015_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.tjog.2025.12.015_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jcph.1978","article-title":"Racial and ethnic differences in drug disposition and response: review of new molecular entities approved between 2014 and 2019","volume":"62","author":"Ramamoorthy","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.tjog.2025.12.015_bib16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.tjog.2025.12.015_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"PAOLA-1\/ENGOT-ov25 investigators. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.tjog.2025.12.015_bib18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/ijgc-2024-005363","article-title":"Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients","volume":"34","author":"Bruno","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.tjog.2025.12.015_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:17:10Z","timestamp":1782854230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455926001592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1028455926001592"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.12.015","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating homologous recombination status and the efficacy\/safety of PARP inhibitors in advanced epithelial ovarianl cancer: A single-institute preliminary experience","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}